U.S. Markets closed

Sesen Bio, Inc. (SESN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.7500-0.1000 (-2.60%)
At close: 4:00PM EDT
3.7500 0.00 (0.00%)
After hours: 07:56PM EDT

Sesen Bio, Inc.

245 First Street
Suite 1800
Cambridge, MA 02142
United States
617 444 8550
http://www.sesenbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees27

Key Executives

NameTitlePayExercisedYear Born
Dr. Thomas R. CannellPres, CEO & Director885.06kN/A1962
Ms. Monica ForbesCFO & Treasurer536kN/A1976
Dr. Glen C. MacDonaldChief Technology Officer519.7kN/A1951
Dr. Gregory L. VerdineCo-FounderN/AN/A1959
Ms. Elly RyuCorp. Controller & Principal Accounting OfficerN/AN/A1981
Ms. Erin ClarkVP of Corp. Strategy & Investor RelationsN/AN/AN/A
Mr. Mark R. SullivanGen. Counsel & Corp. Sec.N/AN/A1971
Mr. Steve BarberaVP of Market AccessN/AN/AN/A
Ms. Julie HoffVP of HRN/AN/AN/A
Dr. David BrooksSr. VP of Clinical Devel.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of BCG-unresponsive NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Sesen Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.